Drugs by condition
Drugs approved for geographic atrophy
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
2
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
1
New molecular entities and new biologics
In development
21
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for geographic atrophy.
All approved drugs for geographic atrophy, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for geographic atrophy
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- VonaprumentANX007Phase 32 trials
Annexon, Inc. · Geographic Atrophy
- BS01Phase 22 trials
Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- APL-3007Phase 21 trial
Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration
- AVD-104Phase 21 trial
Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
- BRX011Phase 21 trial
Biojiva LLC · Geographic Atrophy
- FWY003Phase 21 trial
Novartis · Geographic Atrophy Secondary to Age-related Macular Degeneration
- GAL-101Phase 21 trial
Galimedix Therapeutics Inc · Geographic Atrophy of the Macula
- PST-611Phase 21 trial
Eyevensys · Geographic Atrophy, Age - Related Macular Degeneration (AMD)
- RO7965032Phase 21 trial
Roche (Genentech) · Geographic Atrophy Secondary to Age-Related Macular Degeneration
- SAR446597Phase 21 trial
Sanofi · Geographic Atrophy
- SOM-401Phase 21 trial
Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration
More on geographic atrophy: recruiting trials · published research
Related in ophthalmology: Wet macular degeneration · Diabetic macular edema · Glaucoma · Dry eye disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.